Oklo shares rise as revenue beat offsets wider Q2 loss

Advanced nuclear technology company Oklo Inc. has reported its first-ever quarterly revenue, a significant milestone for the company that has been closely watched by investors betting on a nuclear renaissance. The company's second-quarter 2026 results, released on August 7, showed revenue of $1.2 million—far exceeding analyst consensus estimates—and confirmed that its Groves Isotope Test Reactor in Texas had achieved first criticality. While the company reported a wider net loss due to increased operational expenses, the stock traded sharply higher, reflecting investor optimism about the company's execution and long-term potential .

First Revenue and Financial Performance

Oklo reported second-quarter revenue of $1.2 million, a figure that substantially surpassed analyst expectations. Consensus estimates had projected revenue of approximately $83,800 to $128,000, making the actual result a significant beat . This marks the company's first reported revenue as it transitions from a development-stage enterprise to one beginning to monetize its capabilities.

However, the company reported a net loss of $48.5 million for the quarter, compared with a net loss of $24.7 million in the year-ago period. On a per-share basis, Oklo reported a loss of $0.28, which was wider than the analyst consensus estimate of a $0.16 loss . The increased loss was attributed to higher research, development, and operating expenses as the company continues to scale its business across its three core segments: power, isotopes, and fuel recycling .

For the first six months of 2026, Oklo reported a net loss of $81.6 million, comprised of a loss from operations of $124.2 million, partially offset by $44.5 million in net interest and dividend income . The company ended the second quarter with a robust cash position of $3 billion in cash and marketable securities, consisting of $1.6 billion in cash and equivalents and $1.4 billion in marketable securities. This balance increased by $1.9 billion during the first two quarters following the completion of its at-the-market (ATM) offerings .

Groves Reactor Achieves Criticality

Alongside the financial results, Oklo announced a major technical milestone: its Groves Isotope Test Reactor achieved first criticality in under 11 months from groundbreaking . The low-power test reactor, located near Lockhart, Texas, was built as part of the U.S. Department of Energy's Reactor Pilot Program and is the first reactor under the program to achieve criticality on private land from a greenfield site .

"This milestone comes less than a year after groundbreaking and follows U.S. Department of Energy authorization through the DOE Reactor Pilot Program," the company stated . Oklo co-founder and CEO Jacob DeWitte said the achievement demonstrates that American nuclear deployment timelines can be measured in months rather than years when developers, suppliers, and regulators work together on an integrated approach .

The Groves project is part of Oklo Isotopes' broader effort to build domestic isotope production capabilities for healthcare, industry, research, space, and national security applications. The facility establishes the operational foundation for future commercial isotope production, with initial revenue from the isotope business expected in early 2027 .

Operational Updates and Strategic Positioning

Oklo continues to advance its core Aurora powerhouse business, which is developing fast fission power plants designed to deliver clean, reliable energy at scale. The company has received site use permits from the DOE and is preparing a site near the Idaho National Laboratory for its first commercial reactor, though full construction has not yet begun .

The company has also been expanding its manufacturing and engineering capabilities through acquisitions. During the quarter, Oklo acquired ARMEC and Creative Engineers, which have expanded its in-house capabilities and are expected to shorten feedback loops and support repeatable deployment across projects .

On the fuel supply front, Oklo signed a letter of intent with Centrus to supply HALEU fuel for up to five Aurora powerhouses, with deliveries expected to begin in 2029. The company is also advancing multiple fuel pathways, including commercial HALEU, government plutonium, and recycling, to reduce dependence on a single fuel source .

Oklo has updated its 2026 cash flow guidance, now expecting cash used in operating activities of $120 million to $150 million (up from the prior range of $80 million to $100 million) and capital expenditures of $400 million to $500 million (up from $350 million to $450 million). The increases reflect accelerated procurement and construction activity at Aurora-INL and opportunistic fuel purchases .

Stock Performance and Outlook

Following the earnings release, Oklo shares opened sharply higher, trading up approximately 14.8% to $48.42 during the regular session on August 7 . Despite the positive movement, the stock remains significantly below its 52-week high of $193.84, trading roughly 75% off its peak . Year-to-date, the stock is down approximately 40.9% .

Analysts remain divided on the company's prospects. S&P Global's survey of 25 analysts shows a consensus rating of "Buy" with an average price target of $83.55, implying significant upside from current levels . However, individual targets range from $14 to $130, reflecting the high uncertainty surrounding the company's regulatory path and commercialization timeline . Barclays analyst Christine Cho maintained a "Buy" rating but lowered the price target from $82 to $76 .

The company's $3 billion cash position provides a substantial runway for its development programs, though the aggressive capital deployment and increasing operating losses highlight the execution risks inherent in first-of-a-kind nuclear deployment. Oklo has not yet provided full cost guidance for the Aurora-INL project, leaving investors with limited visibility into total project economics .